Log in with your email address username.


[Correspondence] EXAMINE: targeting risk and treatment in diabetes – Authors’ reply

Giuseppe Derosa and Pamela Maffioli question whether heart failure or mortality outcomes in the EXAMINE1 trial differed according to sex or dose of alogliptin. Post-hoc analyses of these factors have shown no significant heterogeneity between men and women or among the 25 mg, 12·5 mg, and 6·25 mg dose cohorts (dose adjustments were prespecified and based on levels of the estimated glomerular filtration rates) for alogliptin and placebo on these outcomes.